Oestrogen-synthesising enzymes and breast cancer

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1095-1110

  Kulendran, Myutan ^a   Salhab, Mohamed ^b   Mokbel, Kefah ^a,b,c  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b BRUNEL UNIVERSITY   (United Kingdom)

^c Princess Grace Hospital   (United Kingdom)

Author keywords

17 beta HSD type 1; Aromatase; Breast cancer; Carcinogenesis; Estrogen; Postmenopausal; Review; Steroid sulphatase

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; CYTOCHROME P450; ENZYME INHIBITOR; ESTROGEN; ESTROGEN SULFOTRANSFERASE; EXEMESTANE; LETROZOLE; NAFOXIDINE; STERYL SULFATASE; STX 213; STX 64; TAMOXIFEN; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG;

ANEUPLOIDY; ARTICLE; BREAST CANCER; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CELL PROLIFERATION; ENZYME ACTIVITY; ESTROGEN METABOLISM; ESTROGEN SYNTHESIS; GENE CONTROL; GENE EXPRESSION; GENOTOXICITY; HORMONE ACTION; HUMAN; METABOLIC ACTIVATION; MUTATION; NONHUMAN; PATHOGENESIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

17-HYDROXYSTEROID DEHYDROGENASES; ANIMALS; AROMATASE; BREAST NEOPLASMS; ENZYME INHIBITORS; ESTROGENS; HUMANS; HYDRO-LYASES; STERYL-SULFATASE;

EID: 64949155018     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (160)

1. Sasco AJ: Breast cancer and the environment. Horm Res 60: 50, 2003.
2. Henderson IC and Canellos GP: Cancer of the breast: The past decade. N Engl J Med 302: 17-30, 1990.
3. Henderson HS, Ross RK and Bernstein L: Estrogens as a cause of human Cancer: The Richard and Hinda Rosenthal Foundation award Lecture. Cancer Research 48: 246, 1988.
4. Page DL, Dupont WD, Rogers LW and Rados MS: Atypical hyperplastic lesions of the female breast; a longterm follow-up study. Cancer 55: 2698-2708,1985.
5. Russo J, Hasan Lareef M, Balogh G, Guo S and Russo IH: Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J Steroid Biochem Mol Biol 87: 1-25, 2003.
6. Chen S: Aromatase and breast cancer. Front Biosci 3: 922-933, 1998.
7. London SJ, Connolly JL, Schnitt SJ and Colditz GA: A prospective study of benign breast disease and the risk of breast cancer. JAMA 267: 941-944, 1992.
8. Shekhar PVM, Werdell J and Barsrur VS: Environmental estrogen stimulation of growth and estrogen receptor function in preneoplastic and cancerous human breast cell lines. J Natl Cancer Inst 89: 1774-1782, 1997.
9. Dao TL: The role of the ovarian steroid hormones in mammary carcinogenesis. In: Hormones and Breast Cancer, (anbury repport no.8). Pike MC, Siiteri PK and Welsch CW (eds.). Cold Spring Harbor Laboratory Press, Cold Spring Harbor. NY, pp. 281-295, 1981.
10. Wadia PR, Vandenberg LN, Schaeberle CM, Rubin BS, Sonnenschein C and Soto AM: Perinatal bisphenol A exposure increases estrogen sensitivity of the mammary gland in diverse mouse strains. Environ Health Perspect 115: 592-598, 2007.
11. Muñoz-de-Toro M, Markey CM, Wadia PR, Luque EH, Rubin BS, Sonnenschein C and Soto AM: Perinatal exposure to bisphenol-A alters peripubertal mammary gland development in mice. Endocrinology 146: 4138-4147, 2005.
12. Murray TJ, Maffini MV, Ucci AA, Sonnenschein C and Soto AM: Induction of mammary gland ductal hyperplasias and carcinoma in situ following fetal bisphenol A exposure. Reprod Toxicol 23: 383-390, 2007.
13. Pietras RJ, Marquez DC, Chen HW, Tsai E, Weinberg O and Fishbein M: Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 70: 372-381, 2005.
14. Garvin S, Nilsson UW and Dabrosin C: Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells. Br J Cancer 93: 1005-1010, 2005.
15. Maor S, Mayer D, Yarden RI, Lee AV, Sarfstein R, Werner H and Papa MZ: Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Spl. J Endocrinol 191: 605-612, 2006.
16. Redeuilh G, Attia A, Mester J and Sabbah M: Transcriptional activation by the oestrogen receptor alpha is modulated through inhibition of cyclin-dependent kinases. Oncogene 21: 5773-5782, 2002.
17. Yue W, Wang JP, Hamilton CJ, Demers LM and Santen RJ: In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res 58: 927-932, 1998.
18. Planas-Silva MD and Waltz PK: Estrogen promotes reversible epithelial-to mesenchymal-like transition and collective motility in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 104: 11-21, 2007.
19. Sasano H, Okamoto M, Mason JI, Simpson ER, Mendelson CR, Sasano N and Silverberg SG: Immunolocalization of aromatase, 17 alpha-hydroxylase and side-chain-cleavage cytochromes P-450 in the human ovary. Reprod Fertil 85: 163-169, 1989.
20. Sasano H: Functional pathology of human ovarian steroidogenesis: Normal cycling ovary and steroidproducing neoplasms. Endo Pathol 5: 81-89, 1994.
21. Labrie F, Luu-The V, Labrie C, Belanger A, Simard J, Lin SX and Pelletier G: Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 24: 152-182, 2003.
22. Berrino F, Muti P, Micheli A, Bolelli G, Krogh V, Sciajno R, Pisani P, Panico S and Secreto G: Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 88: 291-296, 1996.
23. Lipworth L, Adami HO, Trichopoulos D, Carlstrom K and Mantzoros C: Serum steroid hormone levels, sex hormone-binding globulin, and body mass index in the etiology of postmenopausal breast cancer. Epidemiology 7: 96-100, 1996.
24. Dorgan JF, Stanczyk FZ, Longcope C, Stephenson Jr HE, Chang L, Miller R, Franz C, Falk RT and Kahle L: Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3 beta, 17 beta-diol to risk of breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 6: 177-181, 1997.
25. Sasano H and Harada N: Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocrine Reviews 19: 593-607, 1998.
26. Miller WR: Aromatase activity in breast tissue. J Steroid Biochem Mol Biol 39: 783-790, 1991.
27. Schweikert HU, Milewich L and Wilson JD: Aromatization of androstenedione by cultured human fibroblasts. J Clin Endocrinol Metab 43: 785-795, 1976.
28. Longcope C, Pratt JH, Schneider SN and Fineberg SE: Aromatization of androgens by muscle and adipose tissue in vivo. J Clin Endocrinol Metab 46: 146- 152, 1978.
29. Sasano H, Uzuki M, Sawai T, Nagura H, Matsunaga G, Kashimoto O and Harada N: Aromatase in human bone tissue. J Bone Miner Res 12: 1416-1423, 1997.
30. Santner SJ, Chen S, Zhou D, Korsunsky Z, Martel J and Santen RJ. Effect of androstenedione on growth of untransfected and aromatase-transfected MCF-7 cells in culture. J Steroid Biochem Mol Biol 44: 611-616, 1993.
31. Chetrite GS, Cortes-Prieto J, Philippe JC, Wright F and Pasqualini JR: Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Mol Biol 72: 23-27, 2000.
32. Pasqualini JR, Chetrite G, Blacker C, Feinstein MC, Delalonde L, Talbi M and Maloche C: Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J Clin Endocr Metab 81: 1460-1464, 1996.
33. Pasqualini JR: The selective estrogen enzyme modulators in breast cancer: a review. Biochimica et Biophysica Acta 1654: 123-143, 2004.
34. Reed MJ, Owen AM, Lai LC, Coldham NG, Ghilchik MW, Shaikh NA and James VHT: In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione. Int J Cancer 44: 233-237, 1989.
35. Reed MJ, Purohit A, Howarth NM and Potter BVL: Steroid sulphatase inhibitors: a new endocrine therapy. Drugs Future 19: 673-680, 1994.
36. Miyoshi Y, Ando A, Hasegawa S, Ishitobi M, Taguchi T, Tamaki Y and Noguchi S: High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer. Clin Cancer Res 9: 2288-2293, 2003.
37. Nelson DR, Koymans L, Kamataki T, stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC and Nebert DW: P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6: 1-42, 1996.
38. Chen SA, Besman MJ, Sparkes RS, Zollman S, Klisak I, Mohandas T, Hall PF and Shively JE: Human aromatase: cDNA cloning, Southern blot analysis, and assignment of the gene to chromosome 15. DNA 7: 27-38, 1988.
39. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, Amarneh B, Ito Y, Fisher CR, Michael MD, Mendelson CR and Bulun SE: Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 15: 342-355, 1994.
40. Sebastian S and Bulun SE: A highly complex organization of the regulatory region of the human CYP 19 (Aromatase) gene revealed by the Human Genome Project. J Clin Endocrinol Metab 86: 4600-4602, 2001.
41. Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K, Speed C and Jones M: Aromatase - a brief overview. Annu Rev Physiol 64: 93-127, 2002.
42. Simpson ER: Sources of estrogen and their importance. J Steroid Biochem Mol Biol 86: 225-230, 2003.
43. Nelson LR and Bulun SE: Estrogen production and action. J Am Acad Dermatol 45: 116-124, 2001.
44. Simpson ER and Davis SR: Minireview: Aromatase and the regulation of estrogen biosynthesis- some new perspectives. Endocrinology 142: 4589-4594, 2001.
45. Sebastian S, Takayama K, Shozu M and Bulun SE: Cloning and characterization of a novel endothelial promoter of the human CYP19 (aromatase P450) gene that is up-regulated in breast cancer tissue. Mol Endocrinol 16: 2243-2254, 2002.
46. Harada N: A unique aromatase (P-450arom) mRNA formed by alternative use of tissue-specific exons 1 in human skin fibroblasts. Biochem Biophys Res Commun 189: 1001-1007, 1993.
47. Zhou C, Zhou D, Esteban J, Murai J, Siiteri P.K, Wilczynski S and Chen S: Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction (RT-PCR). J Steroid Biochem Mol Biol 59: 163-171, 1996.
48. Bulun SE, Noble LS, Takayama K, Michael MD, Agarwal V, Fisher C, Zhao Y, Hinshelwood MM, Ito Y and Simpson ER: Endocrine disorders associated with inappropriately high aromatase expression. J Steroid Biochem Mol Biol 61: 133-139, 1997.
49. Simpson ER, Michael MD, Agarwal VR, Hinshelwood MM, Bulun SE and Zhao Y: Cytochromes P450 11: expression of the CYP19 (aromatase) gene: an unusual case of alternative promoter usage. FASEB J 11: 29-36, 1997.
50. Harada N, Utsumi T and Takagi Y: Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissuespecific exons 1 in carcinogenesis. Proc Natl Acad Sci USA 90: 11312-11316, 1993.
51. Esteban JM, Warsi Z, Haniu M, Hall P, Shively JE and Chen S: Detection of intratumoral aromatase in breast carcinomas. Am J Pathol 140: 337-343, 1992.
52. Purohit A, Ghilchik MW, Duncan LJ, Wang DY, Singh A, Walker MM and Reed MJ: Aromatase activity and interleukin 6 production by normal and malignant breast tissues. J Clin Endocrinol Metab 80: 3052-3058, 1995.
53. Singh A, Purohit A, Duncan LJ, Mokbel K, Ghilchik MW and Reed MJ: Control of aromatase in breast tumours: the role of the immune system. J Steroid Biochem Mol Biol 61: 185-192, 1997.
54. Reed MJ, Coldham NG, Patel SR, Ghilchik MW and James VHT: Interleukin-1 and interleukin-6 in breast cyst fluid: their role in regulating aromatase activity in breast cancer cells. J Endocrinol 132: R5-R8, 1992.
55. Reed MJ and Purohit A: Sulphatase inhibitors: the rationale for the development of a new endocrine therapy. Rev Endocr Rel Cancer 45: 51-62, 1993.
56. Miller WR and Mullen P: Factors influencing aromatase activity in the breast. J Steroid Biochem Molec Biol 44: 597-604, 1993.
57. Zhao Y, Nichols JE, Bulnn SE, Mendelson CR and Simpson ER: Aromatase P450 gene expression in human adipose tissue. J Biol Chem 270: 16449-16457, 1995.
58. Singh A, Purohit A, Wang DY, Duncan LJ, Ghilchik MW and Reed MJ: IL-6sR: release from MCF-7 breast cancer cells and role in regulating peripheral oestrogen synthesis. J Endocrinol 147: R9-R12, 1995.
59. Macdiarmid F, Wang DY, Duncan LJ, Purohit A, Ghilchik MW and Reed MJ: Stimulation of aromatase activity in breast fibroblasts by tumour necrosis factor α. Molec Cell Endocr 106: 17-21, 1994.
60. Meng L, Zhou J, Hironobu S, Suzuki T, Zeitoun K and Bulun S: TNFalpha and IL-11 secreted by malignant breast epithelial cells inhibit adipocyte differentiation by selectively down-regulating C/EBPalpha and PPARgamma: mechanism of desmoplastic reaction. Cancer Res 61: 2250-2255, 2001.
61. Agarwal V, Bulun SE, Leitch M, Rohrich R and Simpson ER: Use of alternative promoters to express the aromatase P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J Clin Endocrinol Metab 81: 3843-3849, 1996.
62. Zhao Y, Agarwal VR, Mendelsohn CR and Simpson ER: Transcriptional regulation of CYP19 (aromatase) gene expression in adipose stromal cells in primary culture. J Steroid Biochem Mol Biol 61: 203-210, 1997.
63. Singh A, Purohit A, Ghilchik MW and Reed MJ: The regulation of aromatase activity in breast fibroblasts: the role of interleukin- 6 and prostaglandin E2. Endocr-Relat Cancer 6: 139-147, 1999.
64. Miller WR and O'Neill JS: The importance of local synthesis of estrogen within the breast. Steroids 50: 537-547, 1987.
65. Bulun SE, Price TM, Aitken J, Mahendroo MS and Simpson ER: A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 77: 1622-1628, 1993.
66. Utsumi T, Harada N, Maruta M and Takagi Y: Presence of alternatively spliced transcripts of aromatase gene in human breast cancer. J Clin Endocrinol Metab 81: 2344-2349, 1996.
67. James VHT, McNeill J M, Lai LC, Newton CJ, Ghilchik MW and Reed MJ: Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies. Steroids 50: 269-279, 1987.
68. Zhou D, Pompon D and Chen S: Stable expression of human aromatase cDNA in mammalian cells - A useful system for aromatase inhibitor screening. Cancer Res 50: 6949-6954, 1990.
69. Yue W, Zhou D, Chen S and Brodie A: A new nude mouse model for post.menopausal breast cancer using MCF-7 cells transfected with the htmmn aromatase gene. Cancer Res 54: 5092-5095, 1994.
70. Macaulay VM, Nicholls J E, GledhiU J, Rowlands MG, Dowsett M and Ashworth A: Biological effects of stable overexpression of aromatase in human hormone-dependent breast cancer ceils. Br J Cancer 69: 77-83, 1994.
71. Salhab M, Reed MJ, Al Sarakbi W, Jiang WG and Mokbel K: The role of aromatase and 17-beta hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer. Breast Cancer Res Treat 99: 155-162, 2006.
72. Miller WR, Anderson TJ and Lack WJL: Relationship between tumor aromatase activity, tumor characteristics and response to therapy, fr. Steroid Biochem. Molec Biol 37: 1055-1059, 1990.
73. Sasano H, Nagura H, Harada N, Goukon Y and Kimyra M: Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. Hure Pathol 25: 530-535, 1994.
74. Zhang Z, Yamashita H, Toyama T, Hara Y, Omoto Y, Sugiura H, Kobayashi S, Harada N and Iwase H: Semi quantitative immunohistochemical analysis of aromatase expression in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 74: 47-53, 2002.
75. Brodie A, Lu Q and Nakamura J: Aromatase in the normal breast and breast cancer. J Steroid Biochem Mol Biol 61: 281-286, 1997.
76. The ATAC (Arimidex Tamoxifen alone or in Combination) Trialists' Group, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial, Lancet 359: 2131-2139, 2002.
77. Cunnick GH and Mokbel K: Aromatase inhibitors. Curr Med Res Opin 17: 217-22, 2001.
78. Mokbel K: The evolving role of aromatase inhibitors in breast cancer. Int J Clin Oncol 7: 279-283, 2002.
79. Mokbel R, Karat I and Mokbel K: Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update. Int Semin Surg Oncol 3: 31, 2006.
80. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardly A, Price KN and Goldhirsch A: Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353: 2747-2757, 2005.
81. Luu-The V, Labrie C, Zhao HF, Couet J, Lachance Y, Simard J, Leblanc G, Cote J, Berube D, Gagne R and Labrie F: Characterization of cDNAs for human estradiol 17beta-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 50 -termini in human placenta. J Mol Endocrinol 3: 1301-1309, 1989.
82. Miettinen MM, Mustonen MVJ, Poutanen MH, Isomaa VV and Vihko RK: Human 17b-hydroxysteroid dehydrogenase type 1 and type 2 isozymes have opposite activities in 690 cultured cells and characteristic celland tissue-specific expression. Biochem J 314: 839-845, 1996.
83. Gunnarsson C, Ahnstrom M, Kirschner K, Olsson B, Nordenskjold B, Rutqvist LE, Skoog L and Stal O: Amplification of HSD17B1 and ERBB2 in primary breast cancer. Oncogene 22: 34-40, 2003.
84. Takeyama J, Sasano H, Suzuki T, Iinuma K, Nagura H and Andersson S: 17Betahydroxysteroid dehydrogenase types 1 and 2 in human placenta: an immunohistochemical study with correlation to placental development. J Clinic Endocrinol Metabol 83: 3710-3715, 1998.
85. Takeyama J, Suzuki T, Hirasawa G, Muramatsu Y, Nagura H, Iinuraa K, Nakamura J, Kimura KI, Yoshihama M, Harada N, Andersson S and Sasano H: 17beta-hydroxysteroid dehydrogenase type 1 and 2 expression in the human fetus. J Clinic Endocrinol Metabol 85: 410-416, 2000.
86. Adams EF, Rafferty B and White MC: Interleukin-6 is secreted by breast fibroblasts and stimulates 17 beta oxidoreductase activity in MCF-7 breast cancer cells: possible paracrine regulation of 17beta oestradiol levels. Int J Cancer 49: 118-121, 1991.
87. Duncan LJ, Coldham NG and Reed MJ: The interaction of cytokines in regulating oestradiol 17beta hydroxysteroid dehydrogenase activity in MCF-7 cells. J Steroid Biochem Mol Biol 49: 63-68, 1994.
88. Singh A, Blench I, Morris HR, Savoy LA and Reed MJ: Synergistic interaction of growth factors and albumin in regulating estrogen synthesis in breast cancer cells. Mol Cell Endocrinol 85: 165-173, 1992.
89. Miller WR, Hawkins RA and Forrest APM: Significance of aromatase activity in human breast cancer. Cancer Res 42: 3365-3368, 1982.
90. Perel E, Wilkins D and Killinger DW: The conversion of androstenedione to estrone, estradiol and testosterone in breast tissue. J Steroid Biochem 13: 89-94, 1980.
91. Suzuki T, Moriya T, Ariga N, Kaneko C, Kanazawa M and Sasano H: 17 Beta hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. Br J Cancer 82: 518-523, 2000.
92. Husen B, Huhtinen K, Saloniemi T, Messinger J, Thole HH and Poutanen M: Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts. Endocrinology 747: 5333-5339, 2006.
93. Sasano H, Frost AR, Saitoh R, Harada N, Poutanen M, Vihko R, Buhm SE, Silverberg SG and Nagura H: Aromatase and 17beta hydroxysteroid dehydrogenase type 1 in human breast carcinoma. J Clin Endocrinol Metab 11: 4042-4046, 1996.
94. Suzuki T, Nakata T, Miki Y, Kaneko C, Moriya T, Ishida T, Akinaga S, Hirakawa H, Kimura M and Sasano H: Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res 63: 2762-2770, 2003.
95. Ariga N, Moriya T, Suzuki T, Kimura M, Ohuchi N, Satomi S and Sasano H: 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast. Anticancer Research 20: 1101-1108, 2000.
96. Oduwole OO, Li Y, Isomaa VV, Mantyniemi A, Pulkka AE, Soini Y and Vihko PT: 17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer. Cancer Res 64: 7604-7609, 2004.
97. Zhang Z, Yamashita H, Toyama T, Omoto Y, Sugiura H, Hara Y, Wu X, Kobayashi S and Iwase H: Quantitative determination, by real-time reverse transcription polymerase chain reaction, of aromatase mRNA in invasive ductal carcinoma of the breast. Breast Cancer Res 5: 250-256, 2003.
98. Gunnarsson C, Olsson BM and Stal O: Southeast Sweden Breast Cancer GroupAbnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence. Cancer Res 61: 8448 -8451, 2001.
99. Gunnarsson C, Jerevall PL, Hammar K, Olsson B, Nordenskjöld B, Jansson A and Stål O: Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer. Breast Cancer Res Treat 108: 35-41, 2008.
100. lOO Feigelson SH, McKean-Cowdin R, Coetzee GA, Stram DO, Kolonel LN and Henderson BE: Building a multigenic model of breast cancer susceptibility: CYP 17 and HSD 17 beta 1 are two important candidates. Cancer Res 61: 785-789, 2001.
101. Fischer DS, Allan GM, Bubert C, Vicker N, Smith A, Tutill HJ, Purohit A, Wood L, Packham G, Mahon MF, Reed MJ and Potter BV: E-ring modified steroids as novel potent inhibitors of 17 beta-hydroxysteroid dehydrogenase type 1. J Med Chem 48: 5749-5770, 2005.
102. Bond CS, Clements PR, Ashby SJ, Collyer CA, Harrop SJ, Hopwood JJ and Guss JM: Structure of a human lysosomal sulfatase. Structure 5: 277-289, 1997.
103. Ferrante P, Messali S, Meroni G and Ballabio A: Molecular and biochemical characterisation of a novel sulphatase gene: ary1 sulphatase G (ARSG). Eur J Hum Genet 10: 813-818, 2002.
104. Yen PH, Marsh B, Allen E, Tsai SP, Ellison J, Connoly L, Neiswanger K and Shapiro LJ: The human X-linked steroid sulfatase gene and a Y-encoded pseudogene: evidence for an inversion of the Y chromosome during primate evolution. Cell 55: 1123-1135, 1988.
105. Reed MJ, Purohit A, Woo LW, Newman SP and Potter BV: Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr Rev 26: 171-202, 2005.
106. Purohit A and Reed MJ: Oestrogen sulphatase activity in hormone-dependent and hormone-independent breast cancer cells: modulation by steroidal and non760 steroidal therapeutic agents. Int J Cancer 50: 901-905, 1992.
107. Newman SP, Purohit A, Ghilchik MW, Potter BVL and Reed MJ: Regulation of steroid sulphatase expression and activity in breast cancer. J Steroid Biochem Mol Biol 75: 259-264, 2000.
108. Pasqualini JR, Maloche C, Maroni M and Chetrite G: Effect of the progestagen Promegestone (R-5020) on mRNA of the oestrone sulphatase in the MCF-7 human mammary cancer cells. Anticancer Res 14: 1589-1594, 1994.
109. Reed MJ, Purohit A, Woo LWL and Potter BVL: The development of steroid sulphatase inhibitors. Endocr Rel Cancer 3: 9-23, 1996.
110. Reed MJ, Topping L, Coldham NG, Purohit A, Ghilchik MW and James VHT: Control of aromatase activity in breast cancer cells: the role of cytokines and growth factors. J Steroid Biochem Molec Biol 44: 589-596, 1993.
111. Reed MJ and Purohit A: Inhibition of steroid sulphatases. In: Sandler M, Smith HJ (eds.). Design of enzyme inhibitors as drugs, vol. 2. Oxford: Oxford University Press, pp. 481-494, 1994.
112. Basler E, Grompe M, Parenti G, Yates J and Ballabio A: Identification of point mutations in the steroid sulfatase gene of three patients with X-linked ichthyosis. Am J Hum Genet 50: 483-491, 1992.
113. Alperin ES and Shapiro LJ: Characterization of point mutations in patients with Xlinked ichthyosis. Effects on the structure and function of the steroid sulfatase protein. J Biol Chem 272: 20756-20763, 1997.
114. Poortman J, Andriesse R, Agema A, Douker GH, Schwarz F and Thijssen JHH: In: Adrenal androgen secretion and metabolism in postmenopausal women. Genazzani AR, Thijssen JHH, Siiteri PK (eds.). Adrenal androgens. New York: Raven Press, pp. 219-240, 1980.
115. Poulin R and Labrie F: Stimulation of cell proliferation and estrogenic response by adrenal C19- delta 5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res 46: 4933-4937, 1986.
116. Maggiolini M, Donze O, Jeannin E, Ando S and Picard D: Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor alpha. Cancer Res 59: 4864-4869, 1999.
117. Morris KT, Toth-Fejel SE, Schmidt J, Fletcher WS and Pommier RF: High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy. Surgery 130: 947-953, 2001.
118. Utsumi T, Yoshimura N, Takeuchi S, Maruta M, Maeda K and Harada N: Elevated steroid sulfatase expression in breast cancer. J Steroid Biochem Mol Biol 73: 141-145, 2000.
119. Evans TR, Rowlands MG, Law M and Coombes RC: Intratumoral oestrone sulphatase activity as a prognostic marker in human breast carcinoma. Br J Cancer 69: 555-561, 1994.
120. Utsumi T, Yoshimura N, Takeuchi S, Ando J, Maruta M, Maeda K and Harada N: Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. Cancer Res 59: 377-381, 1999.
121. Al Sarakbi W, Mokbel R, Salhab M, Jiang WG, Reed MJ and Mokbel K: The Role of STS and OATP-B mRNA Expression in Predicting the Clinical Outcome in Human Breast Cancer. Anticancer Res 26: 4985-4990, 2006.
122. Nakata T, Takashima S, Shiotsu Y, Murakata C, Ishida H, Akinaga S, Li PK, Sasano H, Suzuki T and Saeki T: Role of steroid sulfatase in local formation of estrogen in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol 86: 455-460, 2003.
123. Selcer KW, Hegde PV and Li PK: Inhibition of estrone sulfatase and proliferation of human breast cancer cells by nonsteroidal (p-O-sulfamoyl)-N- alkanoyl tyramines. Cancer Res 57: 702-707, 1997.
124. Purohit A, Woo LWL, Potter BVL and Reed MJ: In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE. Cancer Res 60: 3394-3396, 2000.
125. Fischer DS, Chander SK, Woo, Fenton JC, Purohit A, Reed MJ and Potter BV: Novel D-ring modified steroid derivatives as potent, non-estrogenic steroid sulfatase inhibitors with in vivo activity. J Steroid Biochem Mol 84: 343-349, 2003.
126. Foster PA, Newman SP, Chander SK, Stengel C, Jhalli R, Woo LWL, Potter BVL, Reed MJ and Purohit A: In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy. Clin Cancer Res 12: 5543-5549, 2006.
127. Ho YT, Purohit A, Vicker N, Newman SP, Robinson JJ, Leese MP, Ganeshapillai D, Woo LWL, Potter BVL and Reed MJ: Inhibition of carbonic anhydrase II by steroidal and nonsteroidal sulphamates. Biochem Biophys Res Commun 305: 909-914, 2003.
128. Stanway SJ, Purohit A, Woo LWL, Sufi S, Vigushin D, Ward R, Wilson RH, Stanczyk FZ, Dobbs N, Kulinskaya E, Elliott M, Potter BVL, Reed MJ and Coombes RC: Phase I study of STX 64 (667 Coumate) in breast cancer patients: The first study of a steroid sulfatase inhibitor. Clin Cancer Res 12: 1585-1592, 2006.
129. Woo LW, Bubert C, Sutcliffe OB, Smith A, Chander SK, Mahon MF, Purohit A, Reed MJ and Potter BV: Dual Aromatase-Steroid Sulfatase Inhibitors. J Med Chem 26: 3540-60, 2007.
130. Wood PM, Woo LW, Humphreys A, Chander SK, Purohit A, Reed MJ and Potter BV: A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity. J Steroid Biochem Mol Biol 94: 123-130, 2005.
131. Gunasegaram R, Peh KL, Loganath A and Ratnam SS: Expression of 3beta-hydroxysteroid dehydrogenase-5,4-en isomerase activity by infiltrating ductal human breast carcinoma in vitro. Breast Cancer Res Treat 50: 117-123, 1998.
132. Sasano H, Nagura H, Harada N, Goukon Y and Kimura M: Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. Human Pathology 5: 530-533, 1994.
133. Tremblay Y and Beaudoin C: Regulation of 3beta-hydroxysteroid dehydrogenase and 17betahydroxysteroid dehydrogenase messenger ribonucleic acid levels by cyclic adenosine 30 ,50-monophosphate and phorbol myristate acetate in human choriocarcinoma cells. J Mol Endocrinol 7: 355-364, 1993.
134. Gingras S, Moriggl R, Groner B and Simard J: Induction of 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13. J Mol Endocrinol 13: 66-81, 1999.
135. Gingras S, Cote S and Simard J: Multiple signaling pathways mediate interleukin-4-induced 3betahydroxysteroid dehydro-genase/delta5-delta4 isomerase type 1 gene expression in human breast cancer cells. J Mol Endocrinol 14: 229-240, 2000.
136. Aksoy IA, Wood TC and Weinshilboum R: Human liver estrogen sulfotransferase: identification by cDNA cloning and expression. Biochem Biophys Res Commun 200: 1621-1629, 1994.
137. Falany CN, Krasnykh V and Falany JL: Bacterial expression and characterization of a cDNA for human liver estrogen sulfotransferase. J Steroid Biochem Mol Biol 52: 529-539, 1995.
138. Falany JL and Falany CN: Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines. Cancer Research 56: 1551-1555, 1996.
139. Chetrite G, Le Nestour E and Pasqualini JR: Human estrogen sulfotransferase (hESTl) activities and its mRNA in various breast cancer cell lines. Effect of the progestin, promegestone (R-5020). J Steroid Biochem Mol Biol 66: 295-302, 1998.
140. Adams JB, Pewnim T, Chandra DP, Archibald L and Foo MS: A correlation between estrogen sulfotransferase levels and estrogen receptor status in human primary breast carcinoma. Cancer Research 39: 5124-5126,1979.
141. Tseng L, Mazella J, Lee LY and Stone ML: Estrogen sulfatase and estrogen sulfotransferase in human primary mammary carcinoma. J Steroid Biochem 4: 1413-1417, 1983.
142. Pasqualini JR, Chetrite G, Blacker C, Feinstein MC, Delalonde L, Talbi M and Maloche C: Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and post-menopausal breast cancer patients. J Clin Endocrinol Metab 81: 1460-1464, 1996.
143. Huang Z, Fasco MJ, Figge HL, Keyomarsi K and Kaminsky S: Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos 24: 899-905, 1996.
144. Iscan M, Klaavuniemi T, Coban T, Kapucuoglu N, Pelkonen O and Raunio H: The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue. Breast Cancer Res and Treat 70: 47-54, 2001.
145. Hellmold H, Rylander T, Magnusson M, Reihner E, Warner M and Gustafsson JA: Characterization of cytochrome P450 enzymes in human breast tissue from reduction mammaplasties. J Clin Endocrinol Metab 83: 886-895, 1998.
146. El-Rayes BF, Ali S, Heilbrun LK, Lababidi S, Bouwman D, Visscher D and Philip PA: Cytochrome p450 and glutathione transferase expression in human breast cancer. Clin Cancer Res 9: 705-709, 2003.
147. Modugno F, Knoll C, Kanbour-Shakir A and Romkes M: A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat 82: 191-197, 2003.
148. McFadyen MC, Breeman S, Payne S, Stirk C, Miller ID, Melvin WT and Murray GI: Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem 47: 1457-1464, 1999.
149. 0yama T, Morita M, Isse T, Kagawa N, Nakata S, So T, Mizukami M, Ichiki Y, Ono K, Sugaya M, Uramoto H, Yoshimatsu T, Hanagiri T, Sugio K, Kawamoto T and Yasumoto K: Immunohistochemical evaluation of cytochrome P450 (CYP) and p53 in breast cancer. Front Biosci 10: 1156-1161, 2005.
150. Liehr JG: Is estradiol a genotoxic mutagenic carcinogen? Endocrine Reviews 21: 40-54, 2000.
151. Sam KM, Boivin, RP, Tremblay MR, Auger S and Poirier D: C16 and C17 derivatives of estradiol as inhibitors of 17β-hydroxysteroid dehydrogenase type 1: Chemical synthesis and structure-activity relationships. Drug Des and Discov 15: 157-180, 1998.
152. Poirier D, Boivin RP, Bérube M and Lin SX: Synthesis of a first estradiol-adenosine hybrid compound. Bioorganic and Medicinal Chemistry 15: 714-726, 2007.
153. Cadot, C, Laplante, Y, Kamal, F, Luu-The and Poirier D: C6-(N,N-butyl-methyl-heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17β-hydroxysteroid dehydrogenase: Chemical synthesis and biological evaluation. Bioorg Med Chem 15: 714-726, 2007.
154. Allan GM, Vicker N, Lawrence HR, Tutill HJ, Day JM, Huchet M, Ferrandis E, Reed MJ, Purohit A and Barry Potter VL: Novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1: Templates for design. Bioorg Med Chem 16: 4438-4456, 2008.
155. Purohit A, Woo LW, Chander SK, Newman SP, Ireson C, Ho Y, Grasso A, Leese MP, Potter BV and Reed MJ: Steroid sulphatase inhibitors for breast cancer therapy. J Steroid Biochem Mol Biol 86: 423-432, 2003.
156. Jackson T, Woo LW, Trusselle MN, Chander SK, Purohit A, Reed MJ and Potter BV: Dual aromatase-sulfatase inhibitors based on the anastrozole template: synthesis, in vitro SAR, molecular modelling and in vivo activity. Org Biomol Chem 5: 2940-2952, 2007.
157. Wood PM, Woo LWL, Labrosse JR, Trusselle MN, Abbate S, Longhi G, Ettore Castiglioni, Lebon F, Purohit A, Reed MJ and Potter BV: Chiral aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole template: synthesis, absolute configuration, and in vitro activity. J Med Chem 51: 4226-4238, 2008.
158. Thomas JL, Umland TC, Scaccia LA, Boswell EL and Kacsoh B: The higher affinity of human type 1 3beta-hydroxysteroid dehydrogenase (3beta-HSDl) for substrate and inhibitor steroids relative to human 3beta-HSD2 is validated in MCF-7 tumor cells and related to subunit interactions. Endocr Res 30: 935-941, 2004.
159. Dumas NA, He D, Frost AR and Falany CN: Sulfotransferase 2Blb in human breast: Differences in subcellular localization in African American and Caucasian women. J Steroid Biochem Mol Biol 111: 171-177, 2008.
160. Wegman P, Elingarami S, Carstensen J, Stål O, Nordenskjöld B and Wingren S: Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 9: 7, 2007.